QLT, Inc. (QLTI) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- This is Morgan Stanley's only preferred sportswear stock
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- White House copper tariff plan stalls amid affordability concerns, sources say
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
QLT Announces Third Quarter 2014 Results
October 28, 2014 7:00 AM EDTVANCOUVER, British Columbia, Oct. 28, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq: QLTI) (TSX: QLT) ("QLT" or the "Company") is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
2014 THIRD QUARTER FINANCIAL RESULTS
QLT Expenses
Research... More
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer
October 24, 2014 7:00 AM EDTVANCOUVER, British Columbia, Oct. 24, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq: QLTI) (TSX: QLT) ("QLT" or the "Company") today announced that current QLT Board member, Geoffrey F. Cox, Ph.D., has been appointed interim Chief Executive Officer, effective immediately. Dr. Cox brings more than 35 years of business and scientific leadership in the pharmaceutical and biotechnology industries to QLT, 13 years of which have been as Chairman and CEO of public companies. Dr. Cox will continue in his role as a member of the QLT Board of Directors. In conjunction with Dr. Cox's... More
